Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concomitant MenB and MenACWY vaccination in healthy infants
2016-005117-44Phase 3
- Sponsor
- GSK
- Start
- Mar 2017
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of meningococcal group B vaccine and meningococcal conjugate vaccine in meningococcal disease (3 arms), sponsored by GSK. Primary endpoint: hSBA geometric mean titers against serogroup B indicator strains and serogroups A, C, W-135, and Y.
02
Drugs
meningococcal group B vaccinemeningococcal conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2016-005117-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005117-44.